Mishra Shiraz I, Scherer Roberta W, Snyder Claire, Geigle Paula M, Berlanstein Debra R, Topaloglu Ozlem
University of New Mexico, Albuquerque, NM,USA.
Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD008465. doi: 10.1002/14651858.CD008465.pub2.
BACKGROUND: People with cancer undergoing active treatment experience numerous disease- and treatment-related adverse outcomes and poorer health-related quality of life (HRQoL). Exercise interventions are hypothesized to alleviate these adverse outcomes. HRQoL and its domains are important measures of cancer survivorship, both during and after the end of active treatment for cancer. OBJECTIVES: To evaluate the effectiveness of exercise on overall HRQoL outcomes and specific HRQoL domains among adults with cancer during active treatment. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed MEDLINE, EMBASE, CINAHL, PsycINFO, PEDRO, LILACS, SIGLE, SportDiscus, OTSeeker, Sociological Abstracts from inception to November 2011 with no language or date restrictions. We also searched citations through Web of Science and Scopus, PubMed's related article feature, and several websites. We reviewed reference lists of included trials and other reviews in the field. SELECTION CRITERIA: We included all randomized controlled trials (RCTs) and quasi-randomized controlled clinical trials (CCTs) comparing exercise interventions with usual care or other type of non-exercise comparison intervention to maintain or enhance, or both, overall HRQoL or at least one distinct domain of HRQoL. Included trials tested exercise interventions that were initiated when adults with cancer were undergoing active cancer treatment or were scheduled to initiate treatment. DATA COLLECTION AND ANALYSIS: Five paired review authors independently extracted information on characteristics of included trials, data on effects of the intervention, and assessed risk of bias based on predefined criteria. Where possible, we performed meta-analyses for HRQoL and HRQoL domains for the reported difference between baseline values and follow-up values using standardized mean differences (SMDs) and a random-effects model by length of follow-up. We also reported the SMD at follow-up between the exercise and control groups. Because investigators used many different HRQoL and HRQoL domain instruments and often more than one for the same domain, we selected the more commonly used instrument to include in the SMD meta-analyses. We also report the mean difference for each type of instrument separately. MAIN RESULTS: We included 56 trials with 4826 participants randomized to an exercise (n = 2286) or comparison (n = 1985) group. Cancer diagnoses in trial participants included breast, prostate, gynecologic, hematologic, and other. Thirty-six trials were conducted among participants who were currently undergoing active treatment for their cancer, 10 trials were conducted among participants both during and post active cancer treatment, and the remaining 10 trials were conducted among participants scheduled for active cancer treatment. Mode of exercise intervention differed across trials and included walking by itself or in combination with cycling, resistance training, or strength training; resistance training; strength training; cycling; yoga; or Qigong. HRQoL and its domains were assessed using a wide range of measures.The results suggest that exercise interventions compared with control interventions have a positive impact on overall HRQoL and certain HRQoL domains. Exercise interventions resulted in improvements in: HRQoL from baseline to 12 weeks' follow-up (SMD 0.33; 95% CI 0.12 to 0.55) or when comparing difference in follow-up scores at 12 weeks (SMD 0.47; 95% CI 0.16 to 0.79); physical functioning from baseline to 12 weeks' follow-up (SMD 0.69; 95% CI 0.16 to 1.22) or 6 months (SMD 0.28; 95% CI 0.00 to 0.55); or when comparing differences in follow-up scores at 12 weeks (SMD 0.28; 95% CI 0.11 to 0.45) or 6 months (SMD 0.29; 95% CI 0.07 to 0.50); role function from baseline to 12 weeks' follow-up (SMD 0.48; 95% CI 0.07 to 0.90) or when comparing differences in follow-up scores at 12 weeks (SMD 0.17; 95% CI 0.00 to 0.34) or 6 months (SMD 0.32; 95% CI 0.03 to 0.61); and, in social functioning at 12 weeks' follow-up (SMD 0.54; 95% CI 0.03 to 1.05) or when comparing differences in follow-up scores at both 12 weeks (SMD 0.16; 95% CI 0.04 to 0.27) and 6 months (SMD 0.24; 95% CI 0.03 to 0.44). Further, exercise interventions resulted in a decrease in fatigue from baseline to 12 weeks' follow-up (SMD -0.38; 95% CI -0.57 to -0.18) or when comparing difference in follow-up scores at follow-up of 12 weeks (SMD -0.73; 95% CI -1.14 to -0.31). Since there is consistency of findings on both types of measures (change scores and difference in follow-up scores) there is greater confidence in the robustness of these findings.When examining exercise effects by subgroups, exercise interventions had significantly greater reduction in anxiety for survivors with breast cancer than those with other types of cancer. Further, there was greater reduction in depression, fatigue, and sleep disturbances, and improvement in HRQoL, emotional wellbeing (EWB), physical functioning, and role function for cancer survivors diagnosed with cancers other than breast cancer but not for breast cancer. There were also greater improvements in HRQoL and physical functioning, and reduction in anxiety, fatigue, and sleep disturbances when prescribed a moderate or vigorous versus a mild exercise program.Results of the review need to be interpreted cautiously owing to the risk of bias. All the trials reviewed were at high risk for performance bias. In addition, the majority of trials were at high risk for detection, attrition, and selection bias. AUTHORS' CONCLUSIONS: This systematic review indicates that exercise may have beneficial effects at varying follow-up periods on HRQoL and certain HRQoL domains including physical functioning, role function, social functioning, and fatigue. Positive effects of exercise interventions are more pronounced with moderate- or vigorous-intensity versus mild-intensity exercise programs. The positive results must be interpreted cautiously because of the heterogeneity of exercise programs tested and measures used to assess HRQoL and HRQoL domains, and the risk of bias in many trials. Further research is required to investigate how to sustain positive effects of exercise over time and to determine essential attributes of exercise (mode, intensity, frequency, duration, timing) by cancer type and cancer treatment for optimal effects on HRQoL and its domains.
背景:正在接受积极治疗的癌症患者会经历众多与疾病和治疗相关的不良后果,且健康相关生活质量(HRQoL)较差。据推测,运动干预可缓解这些不良后果。HRQoL及其各个领域是癌症患者在积极治疗期间及治疗结束后的重要生存指标。 目的:评估运动对正在接受积极治疗的成年癌症患者的整体HRQoL结局及特定HRQoL领域的有效性。 检索方法:我们检索了Cochrane对照试验中心注册库(CENTRAL)、PubMed MEDLINE、EMBASE、CINAHL、PsycINFO、PEDRO、LILACS、SIGLE、SportDiscus、OTSeeker、Sociological Abstracts,检索时间从建库至2011年11月,无语言或日期限制。我们还通过Web of Science、Scopus、PubMed的相关文章功能以及几个网站检索了文献引用。我们查阅了纳入试验的参考文献列表以及该领域的其他综述。 选择标准:我们纳入了所有比较运动干预与常规护理或其他类型非运动对照干预,以维持或提高,或同时维持和提高整体HRQoL或至少一个HRQoL特定领域的随机对照试验(RCT)和半随机对照临床试验(CCT)。纳入试验测试的运动干预是在成年癌症患者正在接受积极癌症治疗时或计划开始治疗时启动的。 数据收集与分析:五对综述作者独立提取了纳入试验的特征信息、干预效果数据,并根据预定义标准评估了偏倚风险。在可能的情况下,我们使用标准化均数差(SMD)和按随访时间长度的随机效应模型,对报告的基线值与随访值之间的差异进行HRQoL和HRQoL领域的荟萃分析。我们还报告了运动组与对照组在随访时的SMD。由于研究人员使用了许多不同的HRQoL和HRQoL领域工具,且同一领域通常使用不止一种工具,我们选择了更常用的工具纳入SMD荟萃分析。我们还分别报告了每种工具的均数差。 主要结果:我们纳入了56项试验,4826名参与者被随机分配到运动组(n = 2286)或对照组(n = 1985)。试验参与者的癌症诊断包括乳腺癌、前列腺癌、妇科癌症、血液系统癌症和其他癌症。36项试验是在目前正在接受癌症积极治疗的参与者中进行的,10项试验是在癌症积极治疗期间和治疗后进行的,其余10项试验是在计划接受癌症积极治疗的参与者中进行的。运动干预方式因试验而异,包括单独步行或与骑自行车、阻力训练或力量训练相结合;阻力训练;力量训练;骑自行车;瑜伽;或气功。HRQoL及其领域使用了广泛的测量方法。结果表明,与对照干预相比,运动干预对整体HRQoL和某些HRQoL领域有积极影响。运动干预导致以下方面有所改善:从基线到12周随访时的HRQoL(SMD 0.33;95%CI 0.12至0.55),或比较12周随访得分差异时(SMD 0.47;95%CI 0.16至0.79);从基线到12周随访时的身体功能(SMD 0.69;95%CI 0.16至1.22)或6个月时(SMD 0.28;95%CI 0.00至0.55);或比较12周随访得分差异时(SMD 0.28;95%CI 0.11至0.45)或6个月时(SMD 0.29;95%CI 0.07至0.50);从基线到12周随访时的角色功能(SMD 0.48;95%CI 0.07至0.90),或比较12周随访得分差异时(SMD 0.17;95%CI 0.00至0.34)或6个月时(SMD 0.32;95%CI 0.03至0.61);以及在12周随访时的社会功能(SMD 0.54;95%CI 0.03至1.05),或比较12周和6个月随访得分差异时(12周时SMD 0.16;95%CI 0.04至0.27,6个月时SMD 0.24;95%CI 0.03至0.44)。此外,运动干预导致从基线到12周随访时疲劳感减轻(SMD -0.38;95%CI -0.57至 -0.18),或比较12周随访时的随访得分差异时(SMD -0.73;95%CI -1.14至 -0.31)。由于两种测量方法(变化得分和随访得分差异)的结果具有一致性,因此对这些结果的稳健性更有信心。在按亚组检查运动效果时,运动干预对乳腺癌幸存者焦虑的降低作用明显大于其他类型癌症的幸存者。此外,除乳腺癌外的癌症幸存者在抑郁、疲劳和睡眠障碍方面的改善更大,在HRQoL、情绪健康(EWB)、身体功能和角色功能方面也有改善,但乳腺癌幸存者没有。与轻度运动计划相比,规定中度或剧烈运动计划时,HRQoL和身体功能的改善也更大,焦虑、疲劳和睡眠障碍的减轻也更明显。由于存在偏倚风险,本综述的结果需要谨慎解释。所有纳入综述的试验都存在较高的实施偏倚风险。此外,大多数试验存在较高的检测、失访和选择偏倚风险。 作者结论:本系统综述表明,运动可能在不同随访期对HRQoL和某些HRQoL领域产生有益影响,包括身体功能、角色功能、社会功能和疲劳。与轻度强度运动计划相比,运动干预的积极效果在中度或剧烈强度运动计划中更为明显。由于所测试的运动计划和用于评估HRQoL及其领域的测量方法存在异质性,且许多试验存在偏倚风险,因此对这些积极结果必须谨慎解释。需要进一步研究以探讨如何长期维持运动的积极效果,并根据癌症类型和癌症治疗确定运动的基本属性(方式、强度、频率、持续时间、时间),以对HRQoL及其领域产生最佳效果。
Cochrane Database Syst Rev. 2012-8-15
Cochrane Database Syst Rev. 2012-8-15
Cochrane Database Syst Rev. 2018-1-29
Cochrane Database Syst Rev. 2016-11-24
Cochrane Database Syst Rev. 2016-3-31
Cochrane Database Syst Rev. 2018-9-19
Cochrane Database Syst Rev. 2021-10-12
Cochrane Database Syst Rev. 2017-1-3
Cochrane Database Syst Rev. 2017-1-12
Cochrane Database Syst Rev. 2016-8-15
Cancers (Basel). 2025-6-17
Cochrane Database Syst Rev. 2025-5-27
Int J Environ Res Public Health. 2025-3-30
Cochrane Database Syst Rev. 2012-8-15
Cancer Epidemiol Biomarkers Prev. 2011-11-8
Cochrane Database Syst Rev. 2011-10-5